Boosting immunotherapy using human CD3epsilon
Human CD3epsilon co-potentiation to boost immunotherapy
['FUNDING_U01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-11002171
This study is exploring a new way to help the immune system fight non-small cell lung cancer by using special pieces of antibodies that can boost T cells to attack cancer cells, and it's designed for people who are looking for better treatment options.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-11002171 on ClinicalTrials.gov |
What this research studies
This research investigates the potential of a new therapeutic approach that enhances the immune response against cancer by utilizing specific fragments of antibodies that target human CD3epsilon. The study employs a specialized mouse model that mimics human immune responses, allowing researchers to test how effectively these antibody fragments can activate T cells to attack cancer cells, particularly in cases of non-small cell lung cancer (NSCLC). By using patient-derived tumor models, the research aims to provide insights into how this immunotherapy can be optimized for better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who may benefit from enhanced immunotherapy options.
Not a fit: Patients with other types of cancer or those who do not have a suitable immune profile for this treatment may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in using similar antibody-based approaches to enhance immune responses against tumors, indicating potential for success in this area.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GIL PAGES, DIANA — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: GIL PAGES, DIANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer